Drug Database
Back to search

Belgium· BE-AMP-SAM471751-00

Cerdelga 84 mg

A eliglustat product containing eliglustat tartrate, registered in Belgium by Sanofi. The same ATC class is registered in 17 of our 19 countries.

ATC A16AX10

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedCerdelga 84 mgATCA16AX10REGISTER NO.BE-AMP-SAM471751-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about eliglustat tartrateAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Eliglustat is registered in 17 of 19 countries.

Countries holding a registration under ATC A16AX10 (eliglustat), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 11 of them publish a price we can compare per daily dose
Search eliglustat products by name

Eliglustat · ATC A16AX10

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of eliglustat costs, country by country.

Normalised to the WHO defined daily dose (0.168 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Eliglustat · price per daily dose (0.168 g)

USD · FX 28 Sept 2026

  • CH Switzerland$1116.28
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Eliglustat Tartrate
Manufacturer
Sanofi
Country
Belgium (BE)
ATC code
A16AX10
ATC class
Eliglustat
Defined daily dose
0.168 g, O
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    7715378
  • be_apb
    3393857

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

336 interactions on record for eliglustat.

Graded by severity as the source publishes them — 119 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check eliglustat against other medicinesHow interaction checks work

Eliglustat · interactions on record

336 records

  • 119 severe
  • 210 moderate
  • 7 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • CimetidineA02BA01severe
  • DiphenhydraminA04AB05severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Eliglustat in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All eliglustat products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Cerdelga
  • Liechtenstein · Cerdelga
  • Norway · Cerdelga

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/a85427ac-d3f6-45d5-bd21-e7356aaf3839
GET /v1/drugs/a85427ac-d3f6-45d5-bd21-e7356aaf3839?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Cerdelga 84 mg",
  "name_fr": "Cerdelga 84 mg",
  "name_nl": "Cerdelga 84 mg",
  "amp_code": "SAM471751-00",
  "strengths": [
    "84.4000",
    "84.4000",
    "106.0000",
    "106.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Eliglustat Tartrate",
    "Eliglustat",
    "Lactose",
    "Propylene Glycol",
    "Potassium Aluminium Silicate"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Eliglustat",
  "authorisation_numbers": [
    "EU/1/14/974/001",
    "EU/1/14/974/002",
    "EU/1/14/974/003"
  ]
}
API referenceMCP serverPlans

See everything about eliglustat.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console